IMiDs lead to selective ubiquitination and proteasomal degradation of Ikaros and Aiolos through recruiting TFs to the CRL4CRBN E3 ubiquitin ligase, achieving the purpose of therapy for MM and other malignancies. The gene discussed is IKZF3; the disease is Miyoshi myopathy.